Contrasting effects of selective MAGL and FAAH inhibition on dopamine depletion and GDNF expression in a chronic MPTP mouse model of Parkinson's disease

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Neurochemistry International

• Publication date

  2017-11-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.neuint.2017.08.003PMID 28826718
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [Parkinson's disease].

  2022cited by this paper
• Novel pharmacological targets

  2018cited by this paper
• Evaluation of monoacylglycerol lipase as a therapeutic target in a transgenic mouse model of ALS

  2017influential reference
• What failed BIA 10–2474 Phase I clinical trial? Global speculations and recommendations for future Phase I trials

  2016cited by this paper
• Cannabinoid–dopamine interactions in the physiology and physiopathology of the basal ganglia

  2016cited by this paper
• Acute Neurologic Disorder from an Inhibitor of Fatty Acid Amide Hydrolase.

  2016influential reference
• Fatty acid amide hydrolase inhibition for the symptomatic relief of Parkinson's disease.

  2016influential reference
• Neuroprotective Effect of JZL184 in MPP+-Treated SH-SY5Y Cells Through CB2 Receptors

  2016influential reference
• Report by the Temporary Specialist Scientific Committee (TSSC), "FAAH (Fatty Acid Amide Hydrolase)", on the causes of the accident during a Phase 1 clinical trial

  2016cited by this paper
• CB2 receptor activation prevents glial-derived neurotoxic mediator production, BBB leakage and peripheral immune cell infiltration and rescues dopamine neurons in the MPTP model of Parkinson's disease

  2016influential reference
• Potential of the cannabinoid CB(2) receptor as a pharmacological target against inflammation in Parkinson's disease.

  2016cited by this paper
• Cannabinoids in Neurodegenerative Disorders and Stroke/Brain Trauma: From Preclinical Models to Clinical Applications

  2015cited by this paper
• Increasing levels of the endocannabinoid 2-AG is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease

  2015influential reference
• Comparative biochemical characterization of the monoacylglycerol lipase inhibitor KML29 in brain, spinal cord, liver, spleen, fat and muscle tissue.

  2015cited by this paper
• Endocannabinoid Catabolic Enzymes Play Differential Roles in Thermal Homeostasis in Response to Environmental or Immune Challenge

  2015cited by this paper
• GDNF-based therapies, GDNF-producing interneurons, and trophic support of the dopaminergic nigrostriatal pathway. Implications for Parkinson’s disease

  2015cited by this paper
• Parkinson's disease

  2015cited by this paper
• Endocannabinoids drive the acquisition of an alternative phenotype in microglia.

  2015cited by this paper
• Distinct roles of the endocannabinoids anandamide and 2-arachidonoylglycerol in social behavior and emotionality at different developmental ages in rats.

  2015cited by this paper
• Promising cannabinoid-based therapies for Parkinson’s disease: motor symptoms to neuroprotection

  2015cited by this paper
• The therapeutic potential of cannabinoids for movement disorders

  2015cited by this paper
• Cannabinoid Signaling and Neuroinflammatory Diseases: A Melting pot for the Regulation of Brain Immune Responses

  2015cited by this paper
• The influence of cannabinoids on generic traits of neurodegeneration

  2014cited by this paper
• Neuroprotective effects of peroxisome proliferator-activated receptor alpha and gamma agonists in model of parkinsonism induced by intranigral 1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine.

  2014cited by this paper
• Endocannabinoid signalling and the deteriorating brain

  2014cited by this paper
• Monoacylglycerol lipase inhibitor JZL184 is neuroprotective and alters glial cell phenotype in the chronic MPTP mouse model.

  2014cited by this paper
• Actions of the dual FAAH/MAGL inhibitor JZL195 in a murine inflammatory pain model.

  2014cited by this paper
• The fatty acid amide hydrolase inhibitor PF-3845 promotes neuronal survival, attenuates inflammation and improves functional recovery in mice with traumatic brain injury.

  2014cited by this paper
• PPAR-α agonist fenofibrate protects against the damaging effects of MPTP in a rat model of Parkinson's disease.

  2014cited by this paper
• Early phytocannabinoid chemistry to endocannabinoids and beyond

  2014cited by this paper
• Modeling early Parkinson's disease pathology with chronic low dose MPTP treatment

  2013cited by this paper
• Chemical Probes of Endocannabinoid Metabolism

  2013influential reference
• Systems Biology Analysis of the Endocannabinoid System Reveals a Scale-free Network with Distinct Roles for Anandamide and 2-Arachidonoylglycerol

  2013cited by this paper
• Probenecid potentiates MPTP/MPP+ toxicity by interference with cellular energy metabolism

  2013cited by this paper
• Neuroprotective Activities of Palmitoylethanolamide in an Animal Model of Parkinson's Disease

  2012cited by this paper
• Highly selective inhibitors of monoacylglycerol lipase bearing a reactive group that is bioisosteric with endocannabinoid substrates.

  2012cited by this paper
• The fatty acid amide hydrolase (FAAH) inhibitor PF‐3845 acts in the nervous system to reverse LPS‐induced tactile allodynia in mice

  2012cited by this paper
• Symptom‐relieving and neuroprotective effects of the phytocannabinoid Δ9‐THCV in animal models of Parkinson's disease

  2011cited by this paper
• Endocannabinoid Hydrolysis Generates Brain Prostaglandins That Promote Neuroinflammation

  2011influential reference
• Differential role of anandamide and 2-arachidonoylglycerol in memory and anxiety-like responses.

  2011cited by this paper
• Cannabinoid Receptor Type 1 Protects Nigrostriatal Dopaminergic Neurons against MPTP Neurotoxicity by Inhibiting Microglial Activation

  2011influential reference
• Glial cell line-derived neurotrophic factor protects midbrain dopaminergic neurons against lipopolysaccharide neurotoxicity

  2010cited by this paper
• Effects of mitochondrial dysfunction on the immunological properties of microglia

  2010cited by this paper
• Missing pieces in the Parkinson's disease puzzle

  2010cited by this paper
• Microglia and neuroprotection: from in vitro studies to therapeutic applications.

  2010cited by this paper
• Fatty acid amide hydrolase and monoacylglycerol lipase inhibitors produce anti-allodynic effects in mice through distinct cannabinoid receptor mechanisms.

  2010cited by this paper
• Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention.

  2010cited by this paper
• Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system

  2010cited by this paper
• Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo

  2009cited by this paper
• Progressive Dopaminergic Degeneration in the Chronic MPTPp Mouse Model of Parkinson’s Disease

  2009cited by this paper
• WIN55,212‐2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine mouse model of Parkinson’s disease

  2009influential reference
• Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain.

  2009cited by this paper
• Behavior, neurotransmitters and inflammation in three regimens of the MPTP mouse model of Parkinson's disease.

  2009cited by this paper
• The endocannabinoid system as a target for the treatment of motor dysfunction

  2009cited by this paper
• Differences between subacute and chronic MPTP mice models: investigation of dopaminergic neuronal degeneration and α‐synuclein inclusions

  2009cited by this paper
• Intrastriatal inhibition of aromatic amino acid decarboxylase prevents l-DOPA-induced dyskinesia: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine lesioned rats.

  2008cited by this paper
• Modelling Parkinson‐like neurodegeneration via osmotic minipump delivery of MPTP and probenecid

  2008cited by this paper
• Role of CB2 receptors in neuroprotective effects of cannabinoids.

  2008cited by this paper
• Modeling PD pathogenesis in mice: advantages of a chronic MPTP protocol.

  2008cited by this paper
• Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects

  2008cited by this paper
• Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties.

  2007cited by this paper
• Cannabinoids go nuclear: evidence for activation of peroxisome proliferator‐activated receptors

  2007cited by this paper
• Microglia-mediated neurotoxicity: uncovering the molecular mechanisms

  2007cited by this paper
• Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.

  2006cited by this paper
• Novel pharmacological targets for the treatment of Parkinson's disease

  2006cited by this paper
• A Second Fatty Acid Amide Hydrolase with Variable Distribution among Placental Mammals*

  2006cited by this paper
• A role for endocannabinoids in the generation of parkinsonism and levodopa‐induced dyskinesia in MPTP‐lesioned non‐human primate models of Parkinson's disease

  2005cited by this paper
• Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease.

  2005cited by this paper
• The MPTP model of Parkinson's disease.

  2005cited by this paper
• Genetic ablation of tumor necrosis factor‐alpha (TNF‐α) and pharmacological inhibition of TNF‐synthesis attenuates MPTP toxicity in mouse striatum

  2004cited by this paper
• Description of Parkinson's Disease as a Clinical Syndrome

  2003cited by this paper
• CB1 Cannabinoid Receptors and On-Demand Defense Against Excitotoxicity

  2003influential reference
• A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation.

  2002cited by this paper
• The GDNF family: Signalling, biological functions and therapeutic value

  2002cited by this paper
• Neurochemical findings in the MPTP model of Parkinson's disease

  2001cited by this paper
• Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment.

  2001cited by this paper
• Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide.

  2000cited by this paper
• Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease.

  2000cited by this paper
• Fatty acid amide hydrolase, the degradative enzyme for anandamide and oleamide, has selective distribution in neurons within the rat central nervous system

  1997cited by this paper
• Dopaminergic Neurons Protected from Degeneration by GDNF Gene Therapy

  1997cited by this paper
• Neuronal GDNF Expression in the Adult Rat Nervous System Identified By In Situ Hybridization

  1997cited by this paper
• Functional recovery in parkinsonian monkeys treated with GDNF

  1996cited by this paper
• Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides

  1996cited by this paper
• Glial Cell Line‐Derived Neurotrophic Factor Exerts Neurotrophic Effects on Dopaminergic Neurons In Vitro and Promotes Their Survival and Regrowth After Damage by 1‐Methyl‐4‐Phenylpyridinium

  1996cited by this paper
• Effects of probenecid on striatal dopamine depletion in acute and long-term 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice.

  1990cited by this paper
• Regional distribution of brain‐derived neurotrophic factor mRNA in the adult mouse brain.

  1990cited by this paper
• LIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR IS CRUCIAL OR LONG-TERM MAINTENANCE OF THE NIGROSTRIATAL SYSTEM

  year unknowncited by this paper

• Development of cannabinoid-based therapies for Parkinson’s disease: emphasis on targeting cannabinoid receptors as CB2, PPAR-γ and GPR55 receptors

  2026cites this paper
• Cannabinoids, the Blood-Brain Barrier, and Neurodegeneration: Mechanisms, Dysregulation, and Therapeutic Perspectives.

  2026cites this paper
• Neuroprotective and memory-enhancing effects of Aloysia gratissima extract and rutin in an MPTP-induced model of Parkinson's disease.

  2026cites this paper
• Abnormalities of the endocannabinoid system produce piercing nuclear hernias in migrating cerebral neurons

  2025cites this paper
• The Inhibition of Fatty Acid Amide Hydrolase-4 Affords Neuroprotection in a Toxic Model Induced by 6-Hydroxydopamine in Caenorhabditis elegans Nematodes

  2025cites this paper
• Molecular mechanisms of GDNF/GFRA1/RET and PI3K/AKT/ERK signaling interplay in neuroprotection: Therapeutic strategies for treating neurological disorders.

  2025cites this paper
• The role of endocannabinoid signaling in the cytoskeleton functionality in migrating neurons

  2025cites this paper
• Methods for Assessing MAGL Enzymatic Activity: An Extensive Review of Past and Emerging Approaches

  2025cites this paper
• Beyond dopamine: exploring endocannabinoids in Parkinson’s disease

  2024cites this paper
• Preclinical Evaluation of the Reversible Monoacylglycerol Lipase PET Tracer (R)‐[11C]YH132: Application in Drug Development and Neurodegenerative Diseases

  2024cites this paper
• Development of Potent and Selective Monoacylglycerol Lipase Inhibitors. SARs, Structural Analysis, and Biological Characterization.

  2024cites this paper
• Potential Neuroprotective Effect of the Endocannabinoid System on Parkinson's Disease

  2024cites this paper
• Interaction between α-Synuclein and Bioactive Lipids: Neurodegeneration, Disease Biomarkers and Emerging Therapies

  2024cites this paper
• Potential Therapeutic Targets to Modulate the Endocannabinoid System in Alzheimer’s Disease

  2024cites this paper
• Inhibiting degradation of 2-arachidonoylglycerol as a therapeutic strategy for neurodegenerative diseases.

  2023cites this paper
• Insights into the advances in therapeutic drugs for neuroinflammation-related diseases

  2023cites this paper
• Identification of (R)-[18F]YH134 for Monoacylglycerol Lipase Neuroimaging and Exploration of Its Use for Central Nervous System and Peripheral Drug Development

  2023cites this paper
• Roles of the Cannabinoid System in the Basal Ganglia in Parkinson’s Disease

  2022cites this paper
• Polypharmacological Approaches for CNS Diseases: Focus on Endocannabinoid Degradation Inhibition

  2022cites this paper
• Effects of cannabinoids in Parkinson’s disease animal models: a systematic review and meta-analysis

  2022cites this paper
• On the Biomedical Properties of Endocannabinoid Degradation and Reuptake Inhibitors: Pre-clinical and Clinical Evidence

  2021cites this paper
• Inhibiting Monoacylglycerol Lipase Suppresses RANKL-Induced Osteoclastogenesis and Alleviates Ovariectomy-Induced Bone Loss

  2021cites this paper
• Discovery of novel reversible monoacylglycerol lipase inhibitors via docking-based virtual screening.

  2021cites this paper
• Untapped endocannabinoid pharmacological targets: pipe dream or pipeline?

  2021cites this paper
• Neuroprotective and Immunomodulatory Action of the Endocannabinoid System under Neuroinflammation

  2021cites this paper
• In vivo bidirectional modulation of cannabinoid on the activity of globus pallidus in rats.

  2021cites this paper
• Targeting Monoacylglycerol Lipase in Pursuit of Therapies for Neurological and Neurodegenerative Diseases

  2021cites this paper
• Discovery of 8-prenylnaringenin from hop (Humulus lupulus L.) as a potent monoacylglycerol lipase inhibitor for treatments of neuroinflammation and Alzheimer's disease

  2021cites this paper
• First-in-human in vivo imaging and quantification of monoacylglycerol lipase in the brain: a PET study with 18F-T-401

  2021cites this paper
• Interplay Between Endocannabinoid System and Neurodegeneration: Focus on Polypharmacology.

  2021cites this paper
• Bioactive lipids and their metabolism: New therapeutic opportunities for Parkinson's disease

  2021cites this paper
• Conformational gating, dynamics and allostery in human monoacylglycerol lipase

  2020cites this paper
• Development of multitarget inhibitors for the treatment of pain: Design, synthesis, biological evaluation and molecular modeling studies.

  2020cites this paper
• Endocannabinoid modulation of dopamine release during reward seeking, interval timing, and avoidance.

  2020cites this paper
• Remodeling microglia to a protective phenotype in Parkinson's disease?

  2020cites this paper
• Potential application of endocannabinoid system agents in neuropsychiatric and neurodegenerative diseases—focusing on FAAH/MAGL inhibitors

  2020cites this paper
• The Role of Lipids in Parkinson’s Disease

  2019cites this paper
• Optimization of a Benzoylpiperidine Class Identifies a Highly Potent and Selective Reversible Monoacylglycerol Lipase (MAGL) Inhibitor.

  2019cites this paper
• Brain structural changes in cannabis dependence: association with MAGL

  2019cites this paper
• Dimeric c(RGD) peptide conjugated nanostructured lipid carriers for efficient delivery of Gambogic acid to breast cancer

  2019cites this paper
• Monoacylglycerol lipase blockade impairs fine motor coordination and triggers cerebellar neuroinflammation through cyclooxygenase-2.

  2019cites this paper
• Low mRNA expression and activity of monoacylglycerol lipase in human SH-SY5Y neuroblastoma cells.

  2019cites this paper
• Discovery of Trifluoromethyl Glycol Carbamates as Potent and Selective Covalent Monoacylglycerol Lipase (MAGL) Inhibitors for Treatment of Neuroinflammation.

  2018cites this paper
• Neuroprotective effect of crocin on substantia nigra in MPTP-induced Parkinson’s disease model of mice

  2018cites this paper
• Monoacylglycerol lipase (MAGL) as a promising therapeutic target.

  2018cites this paper
• A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017)

  2017cites this paper